Milestone Pharmaceuticals
MIST
25 hedge funds and large institutions have $231M invested in Milestone Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.
242% more capital inflows, than outflows
Capital inflows: $32.9M | Capital outflows: $9.6M
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
9% more funds holding
Funds holding: 23 → 25 (+2)
5.43% more ownership
Funds ownership: 53.37% → 58.8% (+5.4%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tekla Capital Management
Boston,
Massachusetts
|
+$12.4M |
| 2 |
RTW Investments
New York
|
+$7.72M |
| 3 |
OrbiMed
New York
|
+$6.44M |
| 4 |
Acuta Capital Partners
Redwood City,
California
|
+$2.46M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.97M |
| 2 |
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.25M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$250K |
| 4 |
Oxford Asset Management
Oxford,
United Kingdom
|
-$113K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$45.4K |
MIST Hedge Fund Activity: Q4 2019 in Review
25 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2019, worth a combined $231M — down 3.8% from $240M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MIST positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Tekla Capital Management, adding an estimated $12.4M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.97M sold.
- 25 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2019, up from 23 in Q3 2019.
- Funds reported $231M of Milestone Pharmaceuticals stock for Q4 2019, down 3.8% quarter-over-quarter.
- 4 funds opened new Milestone Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of +2 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2019 was Tekla Capital Management, an estimated $12.4M added.
- The largest Milestone Pharmaceuticals seller in Q4 2019 was Baker Bros. Advisors, an estimated $4.97M sold.
Based on aggregated 13F filings for Q4 2019.